Alnylam Pharmaceuticals traded at $231.12 this Thursday October 1st, decreasing $15.62 or 6.33 percent since the previous trading session. Looking back, over the last four weeks, Alnylam Pharmaceuticals lost 13.57 percent. Over the last 12 months, its price fell by 49.86 percent. Looking ahead, we forecast Alnylam Pharmaceuticals to be priced at 250.43 by the end of this quarter and at 234.55 in one year, according to Trading Economics global macro models projections and analysts expectations.
Alnylam Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company's commercial products and pipeline of investigational RNAi therapeutics are focused in four Strategic Therapeutic Areas (STArs): Genetic Medicines, Cardio-Metabolic Diseases, Hepatic Infectious Diseases and CNS/Ocular Diseases. The Company's RNAi-based medicines include ONPATTRO (patisiran), GIVLAARI (givosiran), OXLUMO (lumasiran) and Leqvio (inclisiran). The ONPATTRO (patisiran) is an intravenously administered RNAi therapeutic targeting Transthyretin Amyloidosis (TTR). The GIVLAARI (givosiran) is used to reduce induced liver aminolevulinic acid synthase 1 mRNA, to reduction of toxins associated with attacks and other disease manifestations of Acute Hepatic Porphyria (AHP). The OXLUMO (lumasiran) is an RNAi therapeutic targeting hydroxyacid oxidase 1 for the treatment of Primary Hyperoxaluria Type 1 (PH1). The Leqvio (inclisiran) is used for the treatment of adults with hypercholesterolemia.